E N D
The Pharmacist’s Role in Drug Quality Surveillance: Perspectives from FDA’s Drug Quality Reporting SystemThe Pharmacist’s Role in Drug Product Quality Surveillance: Perspectives from FDA’s Drug Quality Reporting SystemVaiyapuri Subramaniam, Pharm.D., FASHPRalph Jay Schmid, CSORoger Gregorio, CSOFood and Drug AdministrationU.S.A.
Drug QualityReporting System(DQRS) Division of Rx Drug Compliance and Surveillance
DQRS Background • 1971 - 1988 Drug Product Problem Reporting Program (DPPR) • 1988 - Present USP Drug Product Problem Reporting Program (USP Program terminated August 31, 2000) • 1988 - 1993 Drug Quality Reporting System (DQRS) • 1993 - Present MedWatch Program
Program Objectives • Rapidly identify significant health hazards • Detect industry problems and trends • Operate a centralized reporting system
PMST Responsibilities • Screen all reports • Potential Health Hazard • Triage (USP reports) • ADEs • Biologics • Foods • Devices
Responsibilities (Cont’d) • Evaluation of Reports • Collect and Verify Information • Contact reporter • Contact CDER review division • Search Information Sources • DQRS database, DPS surveys, response letters • Reference materials, e.g., Facts and Comparisons • Classification
Classification of Reports • Priority 1 - Imminent or serious health hazard • Priority 2 - Potentially significant CGMP Problems • Priority 3 - Routine follow-up
CDER Interaction • Office of Post-marketing DrugRisk Assessment (OPDRA) • Review divisions • TIACC • GWQAP
Primary Users of the DQRS Database • District Offices Prepare for GMP Inspection • TIACC Investigating therapeutic failures • Drug Survey Identify drugProgram candidates • Office of Identify problem Compliance firms/products • USP Monograph
Total DQRS Reports ReceivedUSP vs MedWatch USP program terminated August 31, 2000
DQRS Reports Resulting In Recalls/Market WithdrawalsRecall Classes FY-96 to FY-01
Recalls/Market Withdrawals Resulting from DQRS ReportsFY-96 to FY-01